Multicenter retrospective and prospective analysis of emicizumab and FVIII prophylaxis in children with severe hemophilia A

被引：0
|
作者：
Hassan, Tamer [1 ]
Lotfy, Gehan [2 ]
Elalfy, Omar [3 ]
Amin, Mervat [4 ]
Elmasry, Zahraa [5 ]
Elhawary, Eslam [6 ]
Darwish, Ahmed [7 ]
Elalfy, Mohsen [8 ]
机构：
[1] Zagazig Univ, Dept Pediat, Zagazig, Egypt
[2] Menia Univ, Menia, Egypt
[3] Natl Res Ctr, Complementary Med Dept, Cairo, Egypt
[4] Assiut Univ, Assiut, Egypt
[5] Sohag Univ, Sohag, Egypt
[6] Tanta Univ, Tanta, Egypt
[7] Mansoura Univ, Mansoura, Egypt
[8] Ain Shams Univ, Cairo, Egypt
来源：
HAEMOPHILIA | 2024年 / 30卷
关键词：
Hemophilia A; Factor VIII; Emicizumab;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LBA-PP-004
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [1] CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis
    Mashiach, Daniel
    Mead, Patrice
    Carneiro, Kendall
    Malvar, Jemily
    Knight, Susan
    Young, Guy
    PEDIATRIC BLOOD & CANCER, 2024, 71 (12)
  • [2] Emicizumab in Children with Severe Hemophilia A
    Thota, Usha Rani
    Martha, Sreelatha
    Ravula, Chaitanya Jyothi
    Cherukuri, Nirmala
    INDIAN JOURNAL OF PEDIATRICS, 2024,
  • [3] Emicizumab Prophylaxis in Children and Adolescents with Hemophilia A
    Hassan, Tamer
    Zakaria, Marwa
    INDIAN JOURNAL OF PEDIATRICS, 2024, 91 (12): : 1297 - 1297
  • [4] CHIEF: A RETROSPECTIVE SELF-CONTROL STUDY OF CHILDREN < 12 WITH SEVERE HEMOPHILIA A WITHOUT INHIBITORS COMPARING EMICIZUMAB TO FVIII
    Mashiach, Daniel
    Mead, Patrice
    Carneiro, Kendall
    Malvar, Jemily
    Young, Guy
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 83 - 84
  • [5] RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB
    Giacomini, E.
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2023, 26 (12) : S69 - S69
  • [6] FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
    Young, Guy
    Eakle, Katherine
    Lim, Elise
    Wang, Michael
    BLOOD, 2024, 144 : 2589 - 2590
  • [7] Health-related quality of life in children with severe hemophilia A on emicizumab prophylaxis
    Hassan, Ahmed S.
    Sherief, Laila M.
    Hamdy, Mona
    Abbas, Ahmed M.
    Elagamy, Osama
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2024, 49 (02): : 192 - 196
  • [8] HAVEN 2: Emicizumab Prophylaxis for Children with Haemophilia A with FVIII Inhibitors
    Young, G.
    Liesner, R.
    Sidonio, R.
    Oldenburg, J.
    Jimenez-Yuste, V.
    Malangu, J.
    Kruse-Jarres, R.
    Wang, M.
    Chang, T.
    Uguen, M.
    Doral, M.
    Schmitt, C.
    Levy, G.
    Shima, M.
    Mancuso, M. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 30 - 31
  • [9] A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
    Young, Guy
    Liesner, Ri
    Chang, Tiffany
    Sidonio, Robert, Jr.
    Oldenburg, Johannes
    Jimenez-Yuste, Victor
    Mahlangu, Johnny
    Kruse-Jarres, Rebecca
    Wang, Michael
    Uguen, Marianne
    Doral, Michelle Y.
    Wright, Lilyan Y.
    Schmitt, Christophe
    Levy, Gallia G.
    Shima, Midori
    Mancuso, Maria Elisa
    BLOOD, 2019, 134 (24) : 2127 - 2138
  • [10] EMICIZUMAB PROPHYLAXIS IN INFANTS WITH SEVERE HEMOPHILIA A: MANAGEMENT OF 6 CASES
    Wang, Cassandra
    Kizilocak, Hande
    Young, Guy
    PEDIATRIC BLOOD & CANCER, 2022, 69
12345